Actinium Pharmaceuticals Overview
Valuation check: ATNM's ROE is 37.32%, above the Healthcare sector average of 22.01%.
Get informed when a big investor buys or sells
+ Follow37.32%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, ATNM shows a ROE of 37.32%. That is above the Healthcare sector average of 22.01%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 22.01%. Actinium Pharmaceuticals is at 37.32%, which is higher that average. That is roughly 69.6% above the sector mean. Use the comparison chart on this page to see how ATNM stacks up against individual peers as well.
Check the historical chart to see whether ATNM's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Actinium Pharmaceuticals with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Actinium Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 37.32%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 22.01%, while ATNM is at 37.32%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
